GB201901608D0 - Vaccine adjuvant conjugates - Google Patents
Vaccine adjuvant conjugatesInfo
- Publication number
- GB201901608D0 GB201901608D0 GBGB1901608.8A GB201901608A GB201901608D0 GB 201901608 D0 GB201901608 D0 GB 201901608D0 GB 201901608 A GB201901608 A GB 201901608A GB 201901608 D0 GB201901608 D0 GB 201901608D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- vaccine adjuvant
- adjuvant conjugates
- conjugates
- vaccine
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1901608.8A GB201901608D0 (en) | 2019-02-06 | 2019-02-06 | Vaccine adjuvant conjugates |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1901608.8A GB201901608D0 (en) | 2019-02-06 | 2019-02-06 | Vaccine adjuvant conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201901608D0 true GB201901608D0 (en) | 2019-03-27 |
Family
ID=65861490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1901608.8A Ceased GB201901608D0 (en) | 2019-02-06 | 2019-02-06 | Vaccine adjuvant conjugates |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB201901608D0 (en) |
Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0549062A2 (en) | 1991-12-23 | 1993-06-30 | Gist-Brocades N.V. | A eukaryotic expression system |
WO1994000153A1 (en) | 1992-06-25 | 1994-01-06 | Smithkline Beecham Biologicals (S.A.) | Vaccine composition containing adjuvants |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
WO1995017210A1 (en) | 1993-12-23 | 1995-06-29 | Smithkline Beecham Biologicals (S.A.) | Vaccines |
WO1996002555A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
WO1996033739A1 (en) | 1995-04-25 | 1996-10-31 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
WO1999042077A2 (en) | 1998-02-19 | 1999-08-26 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
WO2000009159A1 (en) | 1998-08-10 | 2000-02-24 | Aquila Biopharmaceuticals, Inc. | Compositions of cpg and saponin adjuvants and methods thereof |
WO2000062800A2 (en) | 1999-04-19 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
WO2002048187A2 (en) | 2000-12-14 | 2002-06-20 | Phylos, Inc. | Secretion signal peptides, their dna sequences, expression vectors for eukaryotic cells that can be produced with the same, and use thereof for biotechnological production of proteins |
US6573245B1 (en) | 1998-04-28 | 2003-06-03 | Galenica Pharmaceuticals, Inc. | Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof |
WO2004081026A2 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Polypeptides |
WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
WO2006122825A2 (en) | 2005-05-20 | 2006-11-23 | Ablynx Nv | Single domain vhh antibodies against von willebrand factor |
WO2007095506A1 (en) | 2006-02-10 | 2007-08-23 | Invitrogen Corporation | Oligosaccharide modification and labeling of proteins |
WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
WO2010015722A1 (en) | 2008-08-08 | 2010-02-11 | Vib Vzw | Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof |
WO2013036748A1 (en) | 2011-09-09 | 2013-03-14 | Berry, Lana, L. | Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides |
WO2014065661A1 (en) | 2012-10-23 | 2014-05-01 | Synaffix B.V. | Modified antibody, antibody-conjugate and process for the preparation thereof |
WO2015032899A1 (en) | 2013-09-05 | 2015-03-12 | Vib Vzw | Cells producing fc containing molecules having altered glycosylation patterns and methods and use thereof |
WO2015057064A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
WO2015057063A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
WO2015057066A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
WO2015057065A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
WO2015112013A1 (en) | 2014-01-24 | 2015-07-30 | Synaffix B.V. | Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby |
WO2016022027A1 (en) | 2014-08-04 | 2016-02-11 | Synaffix B.V. | Process for the modification of a glycoprotein using a βeta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof |
WO2016053107A1 (en) | 2014-10-03 | 2016-04-07 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
WO2016170186A1 (en) | 2015-04-23 | 2016-10-27 | Synaffix B.V. | PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE |
WO2017005925A1 (en) | 2015-07-09 | 2017-01-12 | Vib Vzw | Cells producing glycoproteins having altered n- and o-glycosylation patterns and methods and use thereof |
-
2019
- 2019-02-06 GB GBGB1901608.8A patent/GB201901608D0/en not_active Ceased
Patent Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0549062A2 (en) | 1991-12-23 | 1993-06-30 | Gist-Brocades N.V. | A eukaryotic expression system |
WO1994000153A1 (en) | 1992-06-25 | 1994-01-06 | Smithkline Beecham Biologicals (S.A.) | Vaccine composition containing adjuvants |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
WO1995017210A1 (en) | 1993-12-23 | 1995-06-29 | Smithkline Beecham Biologicals (S.A.) | Vaccines |
WO1996002555A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
WO1996033739A1 (en) | 1995-04-25 | 1996-10-31 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
WO1999042077A2 (en) | 1998-02-19 | 1999-08-26 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
US6573245B1 (en) | 1998-04-28 | 2003-06-03 | Galenica Pharmaceuticals, Inc. | Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof |
WO2000009159A1 (en) | 1998-08-10 | 2000-02-24 | Aquila Biopharmaceuticals, Inc. | Compositions of cpg and saponin adjuvants and methods thereof |
WO2000062800A2 (en) | 1999-04-19 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
WO2002048187A2 (en) | 2000-12-14 | 2002-06-20 | Phylos, Inc. | Secretion signal peptides, their dna sequences, expression vectors for eukaryotic cells that can be produced with the same, and use thereof for biotechnological production of proteins |
WO2004081026A2 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Polypeptides |
WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
WO2006122825A2 (en) | 2005-05-20 | 2006-11-23 | Ablynx Nv | Single domain vhh antibodies against von willebrand factor |
WO2007095506A1 (en) | 2006-02-10 | 2007-08-23 | Invitrogen Corporation | Oligosaccharide modification and labeling of proteins |
WO2008029281A2 (en) | 2006-02-10 | 2008-03-13 | Invitrogen Corporation | Labeling and detection of post translationally modified proteins |
WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
WO2010015722A1 (en) | 2008-08-08 | 2010-02-11 | Vib Vzw | Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof |
WO2013036748A1 (en) | 2011-09-09 | 2013-03-14 | Berry, Lana, L. | Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides |
WO2014065661A1 (en) | 2012-10-23 | 2014-05-01 | Synaffix B.V. | Modified antibody, antibody-conjugate and process for the preparation thereof |
WO2015032899A1 (en) | 2013-09-05 | 2015-03-12 | Vib Vzw | Cells producing fc containing molecules having altered glycosylation patterns and methods and use thereof |
WO2015057063A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
WO2015057064A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
WO2015057066A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
WO2015057065A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
WO2015112013A1 (en) | 2014-01-24 | 2015-07-30 | Synaffix B.V. | Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained thereby |
WO2016022027A1 (en) | 2014-08-04 | 2016-02-11 | Synaffix B.V. | Process for the modification of a glycoprotein using a βeta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof |
WO2016053107A1 (en) | 2014-10-03 | 2016-04-07 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
WO2016170186A1 (en) | 2015-04-23 | 2016-10-27 | Synaffix B.V. | PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE |
WO2017005925A1 (en) | 2015-07-09 | 2017-01-12 | Vib Vzw | Cells producing glycoproteins having altered n- and o-glycosylation patterns and methods and use thereof |
Non-Patent Citations (33)
Title |
---|
ARNON R. ET AL., PROC. NATL. ACAD. SCI., vol. 77, no. 11, 1980, pages 6769 |
AUSUBEL ET AL.: "current Protocols in Molecular Biology (Supplement 100", 2012, JOHN WILEY & SONS |
CAMPBELL, J.D., DEVELOPMENT OF THE CPG ADJUVANT 1018: A CASE STUDY, 2017, pages 15 - 27, Retrieved from the Internet <URL:https://doi.org/10.1007/978-l-4939-6445-l_2> |
CHASIN ET AL., SOM. CELL MOLEC. GENET., vol. 12, 1986, pages 555 - 556 |
CHEN, B.J.; LESER, G.P.; MORITA, E.; LAMB, R.A.: "Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles", J. VIROL., vol. 81, 2007, pages 7111 - 23, XP055045415, Retrieved from the Internet <URL:https://doi.org/10.1128/JVI.00361-07> DOI: doi:10.1128/JVI.00361-07 |
CHEONG, W.-S.; REISEGER, J.; TURNER, S.J.; BOYD, R.; NETTER, H.-J.: "Chimeric virus-like particles for the delivery of an inserted conserved influenza A-specific CTL epitope", ANTIVIRAL RES., vol. 81, 2009, pages 113 - 122, XP025872395, Retrieved from the Internet <URL:https://doi. rg/10.1016/J.ANTIVIRAL.2008.10.003> DOI: doi:10.1016/j.antiviral.2008.10.003 |
DAVIS ET AL., J. AM. CHEM. SOC., vol. 134, 2012, pages 8030 |
GOLDBLATT D, CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 119, no. 1, 2000, pages 1 - 3 |
GRAHAM ET AL., J. GEN. VIROL., vol. 36, 1977, pages 59 |
HYAKUMURA, M.; WALSH, R.; THAYSEN-ANDERSEN, M.; KINGSTON, N.J.; LA, M.; LU, L.; LOVRECZ, G.; PACKER, N.H.; LOCARNINI, S.; NETTER,: "Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity", J. VIROL., vol. 89, 2015, pages 11312 - 22 |
KERVIEL, A.; DASH, S.; MONCORGE, O.; PANTHU, B.; PRCHAL, J.; DECIMO, D.; OHLMANN, T.; LINA, B.; FAVARD, C.; DECROLY, E.: "Involvement of an Arginine Triplet in M1 Matrix Protein Interaction with Membranes and in M1 Recruitment into Virus-Like Particles of the Influenza A(H1N1)pdm09 Virus", PLOS ONE, vol. 11, 2016, pages e0165421, Retrieved from the Internet <URL:https://doi.org/10.1371/journal.pone.0165421> |
KLEE ET AL., BMC BIOINFORMATICS, vol. 6, 2005, pages 256 |
KOLKEKAR ET AL., BIOCHEMISTRY, vol. 36, 1997, pages 10901 - 10909 |
LAROY, W.; CONTRERAS, R.; CALLEWAERT, N.: "Glycome mapping on DNA sequencing equipment", NAT. PROTOC., vol. 1, 2006, pages 397 - 405, Retrieved from the Internet <URL:https://doi.org/10.1038/nprot.2006.60> |
MATHER, ANNALS NYACAD. SCI., vol. 383, 1982, pages 44 - 68 |
MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251 |
MEIER, S.; GUTHE, S.; KIEFHABER, T.; GRZESIEK, S.: "Foldon, The Natural Trimerization Domain of T4 Fibritin, Dissociates into a Monomeric A-state Form containing a Stable β-Hairpin: Atomic Details of Trimer Dissociation and Local β-Hairpin Stability from Residual Dipolar Couplings", J. MOL. BIOL., vol. 344, 2004, pages 1051 - 1069, XP004635848, Retrieved from the Internet <URL:https://doi.org/10.1016/JJMB.2004.09.079> DOI: doi:10.1016/j.jmb.2004.09.079 |
PARK, A.; HONEY, D.M.; HOU, L.; BIRD, J.J.; ZARAZINSKI, C.; SEARLES, M.; BRAITHWAITE, C.; KINGSBURY, J.S.; KYAZIKE, J.; CULM-MERDE: "Carbohydrate-Mediated Polyethylene Glycol Conjugation of TSH Improves Its Pharmacological Properties", ENDOCRINOLOGY, vol. 154, 2013, pages 1373 - 1383, XP008160851, Retrieved from the Internet <URL:https://doi.org/10.1210/en.2012-2010> DOI: doi:10.1210/en.2012-2010 |
RANNES, J.B.; LOANNOU, A.; WILLIES, S.C.; GROGAN, G.; BEHRENS, C.; FLITSCH, S.L.; TURNER, N.J.: "Glycoprotein Labeling Using Engineered Variants of Galactose Oxidase Obtained by Directed Evolution", J. AM. CHEM. SOC., vol. 133, 2011, pages 8436 - 8439, Retrieved from the Internet <URL:https://doi.org/10.1021/ja2018477> |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR PRESS |
SATO ET AL., SCIENCE, vol. 273, 1996, pages 352 |
SCHAAF ET AL., BMC BIOTECHNOL., vol. 5, 2005, pages 30 |
SHRIMAL, S.; GILMORE, R., J CELL SCI., vol. 126, no. 23, 2013 |
SHUKLA, N.M.; LEWIS, T.C.; DAY, T.P.; MUTZ, C.A.; UKANI, R.; HAMILTON, C.D.; BALAKRISHNA, R.; DAVID, S.A.: "Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines", BIOORG. MED. CHEM. LETT., vol. 21, 2011, pages 3232 - 6, XP028211454, Retrieved from the Internet <URL:https://doi.org/10.1016/j.bmcl.2011.04.050> DOI: doi:10.1016/j.bmcl.2011.04.050 |
SOLTYSIK, S.; WU, J.-Y.; RECCHIA, J.; WHEELER, D.A.; NEWMAN, M.J.; COUGHLIN, R.T.; KENSIL, C.R.: "Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function", VACCINE, vol. 13, 1995, pages 1403 - 1410, XP004057449, Retrieved from the Internet <URL:https://doi.org/10.1016/0264-410X(95)00077-E> DOI: doi:10.1016/0264-410X(95)00077-E |
SUN, S.; ZHANG, H., ANAL. CHEM., vol. 87, no. 24, pages 2015 |
TAN ET AL., PROTEIN ENGINEERING, vol. 15, no. 4, 2002, pages 337 - 345 |
URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 |
VAN GEEL, R.; WIJDEVEN, M.A.; HEESBEEN, R.; VERKADE, J.M.M.; WASIEL, A.A.; VAN BERKEL, S.S.; VAN DELFT, F.L.: "Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates", BIOCONJUG. CHEM., vol. 26, 2015, pages 2233 - 2242, XP055249394, Retrieved from the Internet <URL:https://doi.org/10.1021/acs.bioconjchem.5b00224> DOI: doi:10.1021/acs.bioconjchem.5b00224 |
WANG, J. AM. CHEM. SOC., vol. 134, 2012, pages 12308 |
WU, Z.L.; HUANG, X.; BURTON, A.J.; SWIFT, K.A.D.: "Glycoprotein labeling with click chemistry (GLCC) and carbohydrate detection", CARBOHYDR. RES., vol. 412, 2015, pages 1 - 6, XP055448638, Retrieved from the Internet <URL:https://doi. rg/10.1016/J.CARRES.2015.04.018> DOI: doi:10.1016/j.carres.2015.04.018 |
YOUNIS, S.Y.; BARNIER-QUER, C.; HEUKING, S.; SOMMANDAS, V.; BRUNNER, L.; VD WERFF, N.; DUBOIS, P.; FRIEDE, M.; KOCKEN, C.; COLLIN,: "Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation", BMC IMMUNOL., vol. 19, 2018, pages 6, Retrieved from the Internet <URL:https://doi.org/10.1186/s12865-018-0245-0> |
ZHU, D.; TUO, W.: "QS-21: A Potent Vaccine Adjuvant", NAT. PROD. CHEM. RES., 2015, pages 03, Retrieved from the Internet <URL:https://doi.org/10.4172/2329-6836.1000ell3> |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB202010425D0 (en) | Combination vaccine | |
GB202002166D0 (en) | Vaccine | |
IL292272A (en) | Cancer vaccine | |
EP4213872A4 (en) | Piv5-based covid-19 vaccine | |
GB201704417D0 (en) | Improved li vaccine adjuvant | |
IL284249A (en) | Preparation including vaccine adjuvant | |
GB201910794D0 (en) | Vaccine | |
GB202016954D0 (en) | Vaccine | |
GB2594637B (en) | Novel trypanosomal vaccine | |
GB201901608D0 (en) | Vaccine adjuvant conjugates | |
GB201811382D0 (en) | Vaccine | |
GB201917699D0 (en) | Vaccine conjugates | |
GB202001660D0 (en) | Vaccine adjuvant conjugates | |
GB202119115D0 (en) | Vaccine | |
GB202118110D0 (en) | Vaccine | |
GB202114274D0 (en) | SARS-CoV-2 vaccine | |
GB202112149D0 (en) | Shigellla vaccine | |
GB202102677D0 (en) | Vaccine | |
GB202016165D0 (en) | Vaccine | |
GB202014719D0 (en) | Vaccine | |
GB202013541D0 (en) | Vaccine | |
GB202013534D0 (en) | Vaccine | |
GB202013253D0 (en) | Vaccine | |
GB202009402D0 (en) | Vaccine | |
GB202005880D0 (en) | Vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |